MoonLake Immunotherapeutics (NASDAQ:MLTX) Posts Earnings Results, Misses Estimates By $0.07 EPS

MoonLake Immunotherapeutics (NASDAQ:MLTX) posted its quarterly earnings data on Monday. The company reported ($0.98) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.91) by ($0.07), FiscalAI reports.

MoonLake Immunotherapeutics Price Performance

NASDAQ MLTX traded up $0.15 during trading hours on Wednesday, reaching $18.34. The company’s stock had a trading volume of 531,825 shares, compared to its average volume of 1,693,902. The firm’s 50-day moving average price is $17.49 and its 200-day moving average price is $15.37. The company has a quick ratio of 9.27, a current ratio of 9.27 and a debt-to-equity ratio of 0.24. MoonLake Immunotherapeutics has a 1 year low of $5.95 and a 1 year high of $62.75. The company has a market capitalization of $1.32 billion, a price-to-earnings ratio of -4.73 and a beta of 1.01.

Insider Buying and Selling

In related news, CEO Da Silva Jorge Santos sold 98,127 shares of the business’s stock in a transaction that occurred on Friday, April 10th. The stock was sold at an average price of $18.41, for a total value of $1,806,518.07. Following the transaction, the chief executive officer directly owned 2,976,766 shares of the company’s stock, valued at approximately $54,802,262.06. The trade was a 3.19% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Bvf Partners L. P/Il sold 3,750,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 31st. The stock was sold at an average price of $16.79, for a total value of $62,962,500.00. Following the completion of the transaction, the director directly owned 1,039,238 shares in the company, valued at approximately $17,448,806.02. This represents a 78.30% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 3,900,000 shares of company stock worth $65,714,663. 12.05% of the stock is owned by insiders.

Institutional Trading of MoonLake Immunotherapeutics

Large investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC increased its position in shares of MoonLake Immunotherapeutics by 0.9% during the 2nd quarter. Geode Capital Management LLC now owns 59,553 shares of the company’s stock valued at $2,809,000 after purchasing an additional 559 shares during the last quarter. Squarepoint Ops LLC increased its position in shares of MoonLake Immunotherapeutics by 3.7% during the 2nd quarter. Squarepoint Ops LLC now owns 17,571 shares of the company’s stock valued at $829,000 after purchasing an additional 629 shares during the last quarter. Russell Investments Group Ltd. increased its position in shares of MoonLake Immunotherapeutics by 45.4% during the 4th quarter. Russell Investments Group Ltd. now owns 3,426 shares of the company’s stock valued at $45,000 after purchasing an additional 1,069 shares during the last quarter. BNP Paribas Financial Markets increased its position in shares of MoonLake Immunotherapeutics by 18.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 7,296 shares of the company’s stock valued at $52,000 after purchasing an additional 1,158 shares during the last quarter. Finally, Legal & General Group Plc increased its position in shares of MoonLake Immunotherapeutics by 7.3% during the 2nd quarter. Legal & General Group Plc now owns 20,905 shares of the company’s stock valued at $987,000 after purchasing an additional 1,425 shares during the last quarter. Institutional investors own 93.85% of the company’s stock.

MoonLake Immunotherapeutics News Summary

Here are the key news stories impacting MoonLake Immunotherapeutics this week:

• Positive Sentiment: HC Wainwright raised multiple forward EPS estimates for MoonLake, including Q3 2027, Q4 2027, FY2027 and FY2026, while maintaining a Buy rating and a $45 price target, signaling continued confidence in the company’s long-term outlook. MoonLake Immunotherapeutics stock page
• Positive Sentiment: Needham also increased its price target on MoonLake from $25 to $30 and reiterated a Buy rating, reinforcing the bullish analyst tone around the stock. Benzinga report
• Positive Sentiment: BTIG reiterated a Buy rating and a $30 target, citing a de-risked path to the 2026 BLA filing and robust sonelokimab data, which may have helped lift investor sentiment. TipRanks article
• Positive Sentiment: Reports that MoonLake shares rose after a positive FDA meeting on the sonelokimab filing suggest regulatory progress is improving the market’s view of the company’s development timeline. MSN article
• Neutral Sentiment: HC Wainwright trimmed its Q1 2026 EPS estimate, which is still expected to remain negative as MoonLake continues to operate at a loss. MoonLake Immunotherapeutics stock page
• Neutral Sentiment: The company’s broader earnings outlook remains negative for the next several years, but analysts are gradually improving some quarterly assumptions, suggesting a slowly improving forecast rather than a near-term earnings turnaround. MoonLake Immunotherapeutics stock page

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on MLTX shares. Rothschild & Co Redburn raised MoonLake Immunotherapeutics from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $12.00 to $40.00 in a research report on Thursday, March 19th. BTIG Research reaffirmed a “buy” rating and set a $30.00 price objective on shares of MoonLake Immunotherapeutics in a research report on Monday, March 30th. The Goldman Sachs Group cut MoonLake Immunotherapeutics from a “neutral” rating to a “sell” rating and lifted their price objective for the company from $8.00 to $10.00 in a research report on Wednesday, January 14th. Wolfe Research raised MoonLake Immunotherapeutics from an “underperform” rating to an “outperform” rating and lifted their price objective for the company from $12.00 to $24.00 in a research report on Monday, March 23rd. Finally, Oppenheimer lifted their price objective on MoonLake Immunotherapeutics from $30.00 to $35.00 and gave the company an “outperform” rating in a research report on Tuesday, February 24th. Nine research analysts have rated the stock with a Buy rating, four have given a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat.com, MoonLake Immunotherapeutics currently has a consensus rating of “Hold” and an average price target of $23.85.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.